Radware Schedules Conference Call for Its Second Quarter 2025 Earnings
TEL AVIV, Israel, July 02, 2025 (GLOBE NEWSWIRE) -- Radware® (NASDAQ: RDWR),…
LightSolver and HLRS Present Joint Research on Optical Computingat ISC High Performance 2025
TEL AVIV, Israel, June 10, 2025 (GLOBE NEWSWIRE) -- LightSolver, inventors of…
Microtech Announces the First U.S. Atrial Microsensor Implantations as Part of its FIH Study
TEL AVIV, Israel, June 9, 2025 /PRNewswire/ -- Microtech, a wholly owned…
ImPact Biotech Announces Treatment of First Patient in Phase 1 Clinical Trial of Padeliporfin VTP in Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma (PDAC)
June 05, 2025 16:31 ET  | Source: ImPact Biotech – Previously inoperable…
New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025
More than half of residents with tardive dyskinesia (TD) residing in long-term…
Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TE
Real-world claims studies evaluating UZEDY® (risperidone) also show improved adherence and persistence…